ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies
Sep 26
2024
ÎÚÑ»´«Ã½. (2024).
ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies.
Retrieved from /advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies.
ÎÚÑ»´«Ã½.
"ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies." Hematology.org.
/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies
(label-accessed October 22, 2024).
"ÎÚÑ»´«Ã½."
ASH Letter to FDA re Draft Guidance on Diversity Action Plans for Clinical Studies, 22 Oct. 2024 ,
/advocacy/policy-news-statements-testimony-and-correspondence/testimony-and-correspondence/ash-letter-to-fda-re-draft-guidance-on-diversity-action-plans-for-clinical-studies.
